Real-world experience from the TRIO network assessing outcomes in patients with chronic hepatitis C treated with elbasvir/grazoprevir in the United States

Trial Profile

Real-world experience from the TRIO network assessing outcomes in patients with chronic hepatitis C treated with elbasvir/grazoprevir in the United States

Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Elbasvir/grazoprevir (Primary) ; Ribavirin; Sofosbuvir
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Jun 2018 Updated results (n=319) of retrospective data analyses assessing utilization and outcomes with elbasvir/grazoprevir (EBR/GZR)-containing regimens in an updated cohort of genotype 1B chronic hepatitis C patients treated as part of the TRIO network in the US, presented at the Digestive Disease Week 2018.
    • 05 Jun 2018 Updated results (n=115) presented at the Digestive Disease Week 2018.
    • 17 Apr 2018 Results (n=470) assessing uptake, healthcare utilization and outcomes of chronic hepatitis C treated with elbasvir/grazoprevirin the United States, were published in the Alimentary Pharmacology and Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top